Related Experiment Video
Updated: Mar 15, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.7K
Osteogenic Sarcoma: A 21st Century Review.
Stephen Osasan1, Mingyong Zhang2, Fan Shen3
1Department of Orthopedics, TianYou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, P.R. China Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Anticancer Research
|September 16, 2016
Summary
Bone osteogenic sarcoma (BOS) has a poor prognosis despite chemotherapy advancements. Novel antiproliferative agents like insulin growth factor-binding protein 3 offer new therapeutic targets for this common bone cancer.
Area of Science:
- Oncology
- Orthopedic Oncology
- Biomedical Research
Background:
- Bone osteogenic sarcoma (BOS) remains a challenging bone tumor with unsatisfactory survival rates despite traditional chemotherapy.
- BOS is the most common primary bone cancer, characterized by malignant cells producing immature bone or osteoid.
- Current treatment protocols for BOS have seen little change over the past three decades.
Purpose of the Study:
- To review recent advancements in osteosarcoma research.
- To explore novel therapeutic targets for bone osteogenic sarcoma.
- To bridge the gap between laboratory findings and clinical application in osteosarcoma treatment.
Main Methods:
- Literature review of recent data on osteosarcoma.
- Analysis of chemotherapy effectiveness and limitations.
- Exploration of emerging antiproliferative agents.
Main Results:
- Chemotherapy improved survival rates from <10% to 75% but remains suboptimal.
- Osteosarcoma exhibits diverse morphological presentations with uniform treatment approaches.
- Insulin growth factor-binding protein 3 shows promise as a therapeutic target.
Conclusions:
- Despite chemotherapy's historical impact, new strategies are crucial for improving BOS outcomes.
- Targeted therapies, such as those involving insulin growth factor-binding protein 3, represent a promising frontier.
- Further research is needed to translate novel findings into effective clinical practice for osteosarcoma.
